GlympaTM

Empagliflozin & Linagliptin
SGLT2 Inhibitor & DPP-4 Inhibitor Combination (Antidiabetic Preparations)

Indication:
GlympaTM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

Dosage & Administration:
The recommended dose is GlympaTM 10/ 5 once daily, taken in the morning, with or without food. Dose may be increased to GlympaTM 25/5 once daily.

Preparation:
GlympaTM Tablet: Each box contains 20 tablets in Blister pack.
GlympaTM Tablet: Each box contains 10 tablets in Blister pack.

  • Glympa<sup>TM</sup>
  • Glympa<sup>TM</sup>

  • Products By Trade Name

  • Products By Generic

  • Products By Therapeutic Class

  • Herbal & Nutraceuticals

  • AgroVet & Pesticides